CRSP - CRISPR bluebird stocks slide as Agios rallies on thalassemia study
2024-01-03 13:51:32 ET
More on Agios Pharmaceuticals, bluebird bio, etc.
- Crispr Therapeutics Is Overvalued (Rating Downgrade)
- bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- Agios stock rallies after mitapivat meets key goal in thalassemia trial
- Another CRISPR approval not likely 'any time soon' - report
For further details see:
CRISPR, bluebird stocks slide as Agios rallies on thalassemia study